Market Cap 20.58M
Revenue (ttm) 1.00M
Net Income (ttm) -19.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,999.00%
Debt to Equity Ratio 0.00
Volume 9,000
Avg Vol 30,372
Day's Range N/A - N/A
Shares Out 8.76M
Stochastic %K 26%
Beta 1.04
Analysts Strong Sell
Price Target $23.50

Company Profile

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with a range of anti-cancer regimen...

Industry: Biotechnology
Sector: Healthcare
Phone: 908 842 0100
Address:
110 Allen Road, 2nd Floor, Basking Ridge, United States
PyraWeb
PyraWeb Oct. 22 at 5:25 PM
$LSTA A good listen. I continue to be hyped on the science…but obviously data isnt/hasn’t done much for the company, so I hope Mazzo gets off that and into the $$$ deals. It’s a super thinly traded stock, I hope they release something the market can’t ignore.
0 · Reply
TwongStocks
TwongStocks Oct. 21 at 3:31 PM
$LSTA LD Micro presentation was yesterday. Had a chance to listen to the on-demand replay https://ldmicrocasts.com/ Big takeaway at around the 2:11:15 mark of the video. Seems they are looking to partner out the phase 3 PDAC trial: • Poised for initiation of phase 3 in PDAC • Looking at a combination of raising some capital to contribute to it, but mostly plan to complete development with partners • Looking for potential partners who want to pair certepetide with their checkpoint inhibitor or chemotherapeutic biosimilars • Expect a licensing agreement to complete the phase 3 in pancreatic cancer
2 · Reply
natyar
natyar Oct. 15 at 3:45 PM
$LSTA $PULM undervalued
0 · Reply
TwongStocks
TwongStocks Oct. 14 at 8:18 PM
$LSTA New investor presentation https://ir.lisata.com/static-files/25b9b5e8-eb55-473e-a4cc-b89fa2d4108f • Per slide 7 & slide 50, cash runway is now into Q1 2027 (improved). In the Aug ER, they reported cash runway into Q4 2026. • Slide 48 has upcoming clinical milestones.
0 · Reply
lookingaroundhere
lookingaroundhere Oct. 13 at 6:29 PM
$LSTA data that supports moving into phase 3 - worth a look.
0 · Reply
builderup
builderup Oct. 13 at 5:59 PM
Let’s go! Add these to your lists. It’s almost GO time. $LSTA $MCHX $IVA
0 · Reply
newsfile_corp
newsfile_corp Oct. 13 at 12:01 PM
https://nfne.ws/269816 $LSTA #ldmicro #Publishing #NASDAQ #Investing
0 · Reply
TwongStocks
TwongStocks Oct. 12 at 10:15 PM
$LSTA ESMO Congress abstract is now available https://cslide.ctimeetingtech.com/esmo2025/attendee/confcal_2/presentation/list?q=Ascend&r=pt%7E13 Cohort A vs pooled placebo 6m PFS 49.0% vs 34.1% mPFS 5.6 months 5.3m mOS 12.68m vs 9.23m ORR 35.4% vs 24.5% Cohort B vs pooled placebo 6m PFS 60.8% vs 34.1% mPFS 7.46m vs 5.3m mOS 10.32m vs 9.23m ORR 45.2% vs 24.5%
1 · Reply
Pastures
Pastures Oct. 11 at 7:09 AM
$LSTA Once the results come out how much are people hoping for per share?
1 · Reply
TwongStocks
TwongStocks Oct. 9 at 8:32 PM
$LSTA The pooled Cohort A and Cohort B data from ASCEND will be presented at this month's ESMO Congress in Berlin. Abstract embargo will be lifted at 00:05 CEST (central European summer time) on Oct 13, 6:05pm EDT Oct 12.
1 · Reply
Latest News on LSTA
Lisata Therapeutics to Present at LD Micro Main Event XIX

Oct 13, 2025, 8:00 AM EDT - 12 days ago

Lisata Therapeutics to Present at LD Micro Main Event XIX


Lisata Therapeutics Announces Research License with Catalent

Apr 15, 2025, 8:00 AM EDT - 6 months ago

Lisata Therapeutics Announces Research License with Catalent


Lisata Therapeutics to Present at the Investival Showcase USA

Mar 6, 2025, 8:30 AM EST - 8 months ago

Lisata Therapeutics to Present at the Investival Showcase USA


Lisata Therapeutics, Inc. (LSTA) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 10:06 PM EST - 8 months ago

Lisata Therapeutics, Inc. (LSTA) Q4 2024 Earnings Call Transcript


Lisata Therapeutics to Present at the 2025 Sequire Investor Summit

Jan 15, 2025, 8:30 AM EST - 10 months ago

Lisata Therapeutics to Present at the 2025 Sequire Investor Summit


PyraWeb
PyraWeb Oct. 22 at 5:25 PM
$LSTA A good listen. I continue to be hyped on the science…but obviously data isnt/hasn’t done much for the company, so I hope Mazzo gets off that and into the $$$ deals. It’s a super thinly traded stock, I hope they release something the market can’t ignore.
0 · Reply
TwongStocks
TwongStocks Oct. 21 at 3:31 PM
$LSTA LD Micro presentation was yesterday. Had a chance to listen to the on-demand replay https://ldmicrocasts.com/ Big takeaway at around the 2:11:15 mark of the video. Seems they are looking to partner out the phase 3 PDAC trial: • Poised for initiation of phase 3 in PDAC • Looking at a combination of raising some capital to contribute to it, but mostly plan to complete development with partners • Looking for potential partners who want to pair certepetide with their checkpoint inhibitor or chemotherapeutic biosimilars • Expect a licensing agreement to complete the phase 3 in pancreatic cancer
2 · Reply
natyar
natyar Oct. 15 at 3:45 PM
$LSTA $PULM undervalued
0 · Reply
TwongStocks
TwongStocks Oct. 14 at 8:18 PM
$LSTA New investor presentation https://ir.lisata.com/static-files/25b9b5e8-eb55-473e-a4cc-b89fa2d4108f • Per slide 7 & slide 50, cash runway is now into Q1 2027 (improved). In the Aug ER, they reported cash runway into Q4 2026. • Slide 48 has upcoming clinical milestones.
0 · Reply
lookingaroundhere
lookingaroundhere Oct. 13 at 6:29 PM
$LSTA data that supports moving into phase 3 - worth a look.
0 · Reply
builderup
builderup Oct. 13 at 5:59 PM
Let’s go! Add these to your lists. It’s almost GO time. $LSTA $MCHX $IVA
0 · Reply
newsfile_corp
newsfile_corp Oct. 13 at 12:01 PM
https://nfne.ws/269816 $LSTA #ldmicro #Publishing #NASDAQ #Investing
0 · Reply
TwongStocks
TwongStocks Oct. 12 at 10:15 PM
$LSTA ESMO Congress abstract is now available https://cslide.ctimeetingtech.com/esmo2025/attendee/confcal_2/presentation/list?q=Ascend&r=pt%7E13 Cohort A vs pooled placebo 6m PFS 49.0% vs 34.1% mPFS 5.6 months 5.3m mOS 12.68m vs 9.23m ORR 35.4% vs 24.5% Cohort B vs pooled placebo 6m PFS 60.8% vs 34.1% mPFS 7.46m vs 5.3m mOS 10.32m vs 9.23m ORR 45.2% vs 24.5%
1 · Reply
Pastures
Pastures Oct. 11 at 7:09 AM
$LSTA Once the results come out how much are people hoping for per share?
1 · Reply
TwongStocks
TwongStocks Oct. 9 at 8:32 PM
$LSTA The pooled Cohort A and Cohort B data from ASCEND will be presented at this month's ESMO Congress in Berlin. Abstract embargo will be lifted at 00:05 CEST (central European summer time) on Oct 13, 6:05pm EDT Oct 12.
1 · Reply
emile_
emile_ Oct. 9 at 5:20 PM
$LSTA buy or sell before full ascend trial data?
0 · Reply
EdwardTeach
EdwardTeach Oct. 9 at 5:11 PM
$LSTA someone is holding this down...glta
0 · Reply
Slide3
Slide3 Oct. 9 at 2:31 PM
$LSTA Is the purpose of binding certepetide to an antibody, to get more certepetide into the tumor, or to open the membrane so other drugs and ADCs can enter the tumor, or both?
1 · Reply
TwongStocks
TwongStocks Oct. 9 at 1:25 PM
$LSTA Fierce Biotech article on yesterday's news https://www.fiercebiotech.com/biotech/cdmo-catalent-strengthens-adc-pipeline-10m-pact-lisata-tumor-drug
0 · Reply
Slide3
Slide3 Oct. 8 at 3:53 PM
$LSTA I think whatever big boys who support this stock were not informed beforehand and are holding it down to accumulate more. That's my story and I'm staying with it . Catalent was supposed to report their decision in June and took 4 months extra, either it was technically difficult or they were very interested in what they found. If this news doesn't really the stock eventually, someone will buy it. JMO DYODD
0 · Reply
emile_
emile_ Oct. 8 at 3:25 PM
$LSTA market thinks that the Catalent license deal will not go far from preclinical?
1 · Reply
EdwardTeach
EdwardTeach Oct. 8 at 3:08 PM
$LSTA this is the loading zone....glta
0 · Reply
m1ster_leboeuf
m1ster_leboeuf Oct. 8 at 2:13 PM
0 · Reply
Slide3
Slide3 Oct. 8 at 1:46 PM
$LSTA Amazing, the market is asleep on this. Merck invested $6 billion in ADCs , they're not going to want to enhance their penetration?
0 · Reply
drwaz
drwaz Oct. 8 at 1:24 PM
$LSTA This will run
0 · Reply
EdwardTeach
EdwardTeach Oct. 8 at 1:13 PM
$LSTA "Under the terms of the agreement, Lisata is eligible to receive over $10 million in tiered study initiation milestone payments plus revenue sharing on future sales and partnerships." "Catalent gains global rights to evaluate certepetide for ADC payloads" https://in.investing.com/news/company-news/catalent-gains-global-rights-to-evaluate-certepetide-for-adc-payloads-93CH-5035340
0 · Reply
PyraWeb
PyraWeb Oct. 8 at 1:08 PM
$LSTA awesome news! A deal with Catalent! This is what we are looking for! Now let’s see how the stupid market reacts. Hopefully this finally gets a ton of volume.
1 · Reply